Centrophenoxine (meclofenoxate) is a drug related to DMAE. It is prescribed in China and elsewhere for conditions such as dementia and alcoholism, but FDA has not approved it for any use (Cohen 2022).
Also known as: meclofenoxate, meclofenoxate hydrochloride.
There is no FDA-approved product. When 7 US supplements were tested, they held 79 to 251 mg per serving, and only 1 of 7 matched its label within 10% (Cohen 2022).
Centrophenoxine is not FDA approved for any use (Cohen 2022). WADA's 2026 Prohibited List names meclofenoxate under S6.B, specified stimulants, prohibited in competition.
When researchers bought 7 US products labeled as dietary supplements containing centrophenoxine, all contained it; at the label's maximum daily intake, users would take 237 to 752 mg a day, and only 1 product listed an amount within 10% of what it held (Cohen 2022).
What studies show: evidence in people is old and thin. A 2018 Cochrane review of cholinergic drugs, which included meclofenoxate, for tardive dyskinesia (a movement side effect of antipsychotics) found the effects unclear because the trials were too few and too small (Tammenmaa-Aho 2018). Athletes subject to drug testing should treat it as a banned substance.
Meclofenoxate is a prodrug: it is broken down so quickly that it is not found in blood, and studies measure its breakdown product, 4-chlorophenoxyacetic acid, instead (Zou 2008). The abstract does not give a half-life, so we do not list one.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator